NEW YORK – Burning Rock has started a 14,000-patient trial called the Pan-Cancer Early Detection Project (PREDICT) to further validate its cell-free DNA early detection technology.
The oncology-focused, Shanghai-based molecular diagnostics firm is working with the Shanghai Zhongshan Hospital and other medical centers to enroll thousands of patients into PREDICT with the goal of validating its cfDNA test in multiple tumor types. The test, which Burning Rock has been developing for four years, is based on its ELSA-seq technology and gauges methylation profiles.